Abdulah Alrifai, MD
Cardiovascular Disease · Hazel Crest, ILNPI 1265774616
Payments from drug & device makers
Across 221 payments — averaging $208.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$19K
- Inari Medical, Inc.$8K
- Abbott$7K
- Surmodics, Inc.$6K
- Medtronic$2K
- Edwards Lifesciences$1K
- plus $3K from 24 others
What the payments were for
- Consulting fees$3,1507%
- Speaking & faculty fees$21,05046%
- Travel & lodging$11,44725%
- Food & beverage$10,10422%
- Education$2851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 32 | $18,815 |
| Inari Medical, Inc. | 16 | $8,239 |
| Abbott | 58 | $7,362 |
| Surmodics, Inc. | 13 | $5,588 |
| Medtronic(2 entities) | 24 | $1,771 |
| Edwards Lifesciences | 10 | $1,096 |
| Boston Scientific | 6 | $376 |
| Angiodynamics, Inc. | 3 | $313 |
| Novo Nordisk | 5 | $263 |
| Imperative Care, Inc | 3 | $255 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $232 |
| Endologix LLC | 2 | $197 |
| Tactile Systems Technology Inc | 9 | $195 |
| Cardiovascular Systems Inc. | 1 | $184 |
| Johnson & Johnson | 5 | $179 |
| Atricure, Inc. | 1 | $178 |
| Boehringer Ingelheim | 3 | $172 |
| BD | 1 | $153 |
| Philips North America LLC | 5 | $123 |
| Astellas Pharma US Inc | 2 | $93 |
| AstraZeneca | 4 | $55 |
| Stryker | 1 | $35 |
| Cardiva Medical, Inc. | 1 | $25 |
| Novartis | 1 | $24 |
| Argon Medical Devices, Inc. | 1 | $23 |
| Amgen | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Terumo Medical Corporation | 1 | $19 |
| Abiomed | 1 | $15 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$16,888
- FLOWTRIEVER CATHETER, S$7,899
- CT THROMBECTOMY SYSTEM KIT$7,899
- Pounce Venous Thrombectomy System$5,314
- Omnilink Elite vascular stent system$2,701
- Xience V coronary stent system$1,611
- Sublime 014 Rx PTA Balloon Dilatation Catheter$1,472
- Sublime Microcatheter, 018, 200cm, Straight$1,472
- Pounce Thrombectomy System$1,472
- Pounce Thrombectomy$1,472
- Penumbra Coil 400$1,418
- OPTIS$1,302
- CoreValve Evolut$651
- Auryon Laser System 100-120 Vac$243
- ZOOM 88-T LARGE DISTAL PLATFORM$211
- Integrity$210
- Diamondback Coronary$184
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$178
- RotarexS 6 F x 135 cm$153
- ENDOCROSS Device$147
How this compares
$46,035 in reported general payments places this provider in the 85th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $102,653 |
| EntrestoSacubitril/Valsartan | 37 | $50,726 |
| JardianceEmpagliflozin | 27 | $39,825 |
| XareltoRivaroxaban | 16 | $25,039 |
| Repatha SureclickEvolocumab | 16 | $11,322 |
| Praluent PenAlirocumab | 13 | $6,140 |
| Atorvastatin Calcium | 194 | $1,721 |
| ClopidogrelClopidogrel Bisulfate | 140 | $1,721 |
| Metoprolol Succinate | 102 | $1,549 |
| Cilostazol | 34 | $1,144 |
| Valsartan | 19 | $948 |
| Carvedilol | 113 | $802 |
| Amlodipine Besylate | 110 | $767 |
| Hydralazine Hcl | 29 | $694 |
| Losartan Potassium | 39 | $675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $24 | $50,72637 claims |
| Boehringer IngelheimJardiance | $172 | $39,82527 claims |
| Johnson & JohnsonXarelto | $179 | $25,03916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Hazel Crest
- Lokesh ChandraHazel Crest$2.7M
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Steven LupovitchArlington Heights$2.6M
- Nitasha SarswatChicago$2M
- Alan BrownNaperville$1.5M
- Alexander AdlerPeoria$1.5M
- Clifford KavinskyMaywood$1.4M
- Sanjiv ShahChicago$1.2M
- Sandeep NathanChicago$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.